ARVN / Arvinas: Promising Science, Poor Data

Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not hel more_horizontal

Arvinas focuses on protein degradation therapies, with current projects targeting breast and prostate cancers. Financially, ARVU holds robust liquidit more_horizontal

NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drug more_horizontal

Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.67. This compares to loss o more_horizontal

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for more_horizontal

Arvinas, Inc. has exciting science, but data has been a disappointment. There are no near-term major catalysts for Arvinas. Arvinas has a lot of cash, more_horizontal

Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.54 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to loss o more_horizontal

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for more_horizontal